Natalizumab, Efalizumab, and Progressive Multifocal Leukoencephalopathy (PML)

Project Title Natalizumab, Efalizumab, and Progressive Multifocal Leukoencephalopathy (PML)
Date Posted
Thursday, January 10, 2013
Project ID

Modular program-based one-time assessment of the risk of progressive multifocal leukoencephalopathy (PML) associated with use of natalizumab and efalizumab in the Mini-Sentinel Distributed Database. Modular programs are adaptable standardized programs. Queries were executed in May 2012.

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by clicking on the Submit Comments link above or sending an email requesting assistance to

The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer.

Medical Product
Health Outcome
progressive multifocal leukoencephalopathy (PML)
Time Period
2003 - 2011
Assessment Type
Exploratory Analyses
Study Type
Modular Program
Data Sources
Mini-Sentinel Distributed Database (MSDD)
FDA Center
Scroll to Top